News

Researchers from the Rowan University School of Osteopathic Medicine have reported the ongoing development of a blood test for early Alzheimer’s’ disease diagnostic. The preliminary data was presented during the recent Osteopathic Medical Conference & Exposition (OMED 15) in Orlando, Florida. The innovative blood test relies on the detection of autoantibodies as blood biomarkers of…

A new study reports the finding of fungal cells and hyphae in tissue from different regions of the central nervous system (CNS) in Alzheimer’s disease (AD) patients. The research article, entitled “Different Brain Regions are Infected with Fungi in Alzheimer’s Disease”, was published in Scientific Reports. AD…

Findings from a recent study published in the British Journal of Psychiatry revealed that antipsychotic drugs are used by Alzheimer’s disease (AD) patients more frequently than in the general population — already 2-3 years before an Alzheimer’s diagnosis. The team of researchers from the University of Eastern Finland also…

In a study recently published in the journal Brain a team of researchers found an immune system gene associated with higher rates of amyloid plaque buildup in the brains of patients with Alzheimer’s Disease and older adults at risk for the condition. The mechanisms underlying amyloid…

Clinical-stage biopharmaceutical company Anavex Life Sciences Corp. is working on an investigational oral treatment for Alzheimer’s disease called ANAVEX 2-73, with full PART A data and preliminary PART B data from its ongoing Phase 2a clinical trial to be presented during the Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 5 and…

In a new study entitled “Histone Deacetylase Inhibition via RGFP966 Releases the Brakes on Sensory Cortical Plasticity and the Specificity of Memory Formation” a team of researchers at Rutgers University discovered that the drug RGFP966 changes how audible memory is formed and that RGFP966-treated rats have stronger memories that…

Clinical-stage biopharmaceutical company, Axovant Sciences Ltd., recently announced it has screened the first batch of patients for MINDSET, an international Phase III clinical trial exploring RVT-101 as a candidate treatment for Alzheimer’s disease. The company also reported the US Food and Drug Administration’s decision to grant MINDSET a Special Protocol Assessment…

Researchers at University of Southern California at Los Angeles (USC) Viterbi School of Engineering and Wake Forest Baptist Medical Center in Winston-Salem, North Carolina have developed a brain prosthesis designed to help individuals suffering from memory loss associated with Alzheimer’s Disease (AD) and other forms of dementia form new…

As a disease that is best detected and treated early after onset, Alzheimer disease is characterized by a variety of aberrantly regulated proteins and molecules, which once identified can be used as biomarkers for disease and integrated into Alzheimer’s diagnostic tests. New research at the University of Illinois at Chicago by co-authors Dr.

A recent communication from the University of Texas at Arlington reported that computer scientists led by Professor Heng Huang won a $2 million grant funded by the National Institutes of Health to investigate the possibility of predicting whether a person is predisposed to develop Alzheimer’s disease by analyzing complex genomics data.